-+ 0.00%
-+ 0.00%
-+ 0.00%

IRLAB Therapeutics Q3 Operating Loss Narrows 25% to SEK 12.94 Million

PUBT·11/13/2026 06:31:40
Listen to the news
IRLAB Therapeutics Q3 Operating Loss Narrows 25% to SEK 12.94 Million
  • IRLAB Therapeutics’ third-quarter 2026 loss narrowed 35% year over year to SEK 13.15 million.
  • Net sales fell 63% year over year to SEK 6.93 million.
  • Quarter-end cash and cash equivalents declined 18% year over year to SEK 90.64 million.
  • IRLAB is initiating workforce reductions to focus resources on revenue generation, with new partnership agreements less likely in 2026.
  • Management flagged going-concern uncertainty and is pursuing collaborations, licensing arrangements or additional capital-market funding.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRLAB Therapeutics AB published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.